Ceva Animal Health has introduced an improved version of Hepatosyl, its liver support supplement for horses.
Hepatosyl Plus for horses contains the same antioxidant ingredients as the original version but now also contains Silybin, the most active isomer of Silybum marianum (milk thistle)1.
According to Ceva, the addition of Silybin gives new Hepatosyl Plus a triple antioxidant approach to liver support to help neutralise free radicals within the liver. Free radicals are produced by hepatocyte mitochondria and cause oxidative damage to cell membranes, protein and DNA.
The company says Hepatosyl Plus's triple approach includes S-adenosylmethionine (SAMe), in a stable, pure and absorbable form, which is converted into the potent liver anti-oxidant glutathione and also helps to maintain bile flow; Vitamin E, which is well-known as a potent liver antioxidant, and Silybin, which works as an antioxidant by increasing cellular superoxide dismutase.
Hepatosyl Plus remains the only liver supplement to contain Vitamin K which is needed by the liver for the production of many essential clotting factors, such as factors II, VII, IX and X, making it ideally suited for pre and post anaesthetic liver support.
Ceva says an independent trial2 on horses with confirmed liver disease has demonstrated the benefits of Hepatosyl. Conducted by European Specialist in equine internal medicine Dr Tim Brazil, the trial involved seven horses of various ages and types. All animals were given Hepatosyl in addition to treatment with antimicrobials, corticosteroids, a low protein diet and vitamin B supplementation. Post SAMe supplementation tests revealed a notable reduction in raised liver enzymes, serum proteins and bile acids and the seven horses showed obvious improvements including better appetite, weight gain and demeanour.
For further product information contact Ceva Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
References1 Flatland B (2003) Botanicals, Vitamins and Minerals and the Liver2 Brazil T (2007) S-adenosylmethionine liver support supplement trial in horses
Faecal calprotectin is a calcium-binding protein released into the gut lumen predominantly by neutrophils, and to a lesser extent by monocytes and macrophages, during intestinal inflammation.
Its presence in faeces reflects the degree of neutrophilic infiltration in the gut mucosa, making it a useful biomarker for identifying intestinal inflammation.
Faecal calprotectin lateral flow testing is already used in human health and included in the NICE guidelines for the management of inflammatory bowel disease (IBD)1.
Determining the underlying cause of chronic diarrhoea, vomiting and weight loss in cats and dogs can be complex, often requiring invasive procedures such as endoscopy or biopsy - both of which carry cost, risk, and sometimes practical limitations in general practice.
GIQuest is designed to offer a non-invasive, rapid alternative to support clinical decision-making.
Carus says that whilst not a replacement for histopathology, faecal calprotectin concentrations have been shown to correlate with disease severity in dogs and cats, as measured by tools such as the Canine Chronic Enteropathy Clinical Activity Index (CCECAI).2
New data from the University of Bristol Vet School appears to confirm the test’s ability to differentiate dogs with histologically-confirmed inflammatory enteropathy from healthy controls with high sensitivity (94%) and specificity (96%) using a score threshold of 3mg/kg.2
Carus says the test also performed well in cats, distinguishing those with inflammatory enteropathy from healthy controls with a specificity of 100% and sensitivity of 92%.
In addition, the test detected elevated calprotectin levels consistent with inflammatory gastroenteropathy in 25% of dogs receiving oral NSAIDs, which highlights its potential not only in long-term monitoring but also early in treatment when GI side effects may first emerge.
Jolian Howell of Carus Animal Health said: “Faecal calprotectin testing can provide additional clarity in a range of clinical scenarios.
"It is particularly useful when diagnosing and managing suspected inflammatory enteropathy or food related reactions and for monitoring or screening for GI side effects of oral non-steroidal anti-inflammatories in long term OA therapy regimes.”
The Bristol study also showed that dogs with food-responsive enteropathy had a significant drop in calprotectin concentrations following dietary change, reinforcing the test’s role in tracking treatment response.
Georgie Louca, Veterinary Business Manager for Carus Animal Health, added: ”By providing a measurable, visual indicator of intestinal inflammation, GIQuest also helps support client communication and can improve compliance during treatment or dietary trials.”
GIQuest is designed for use in practice, including during consultations, delivering colour-coded results in 15 minutes.
GIQuest is now available to veterinary practices across the UK and can be ordered through veterinary wholesalers NVS, Covetrus and MWI.
https://carusanimalhealth.com/giquest
References
The extension includes a new diagnostic imaging suite with both CT and MRI scanners, a fourth operating theatre, two more consulting rooms, an additional ward for dogs and an expanded office for clinicians.
North Downs hospital director Terry Emmerson said: "This significant investment illustrates our commitment to providing the highest standards of medical and surgical care for our pets in a caring, compassionate environment.
"It has provided us with a number of important new facilities, allowing us to continue to build on our services and our level of care.
As part of the expansion, North Downs has also recruited five more clinicians, two specialising in small animal surgery, one in neurology, one in ophthalmology and one in anaesthesia.
Mr Emmerson said: "All the investment in facilities and technology is very important and exciting but we also recognised the need to invest in recruiting more talented staff to help us make the most of it all.
"That’s why we have added five new clinicians in several key disciplines and in turn increased the size of our clinicians’ office to help incorporate those additional staff.
"It all means we can now offer an even better service, leading facilities and treatment within a far more structured and organised layout which helps makes everything more efficient and user-friendly for staff and patients."
For more information about North Downs Specialist Referrals, visit www.ndsr.co.uk.
Zoetis has announced the launch of Simparica, a once-monthly oral medication for the treatment of flea, tick and mite infestations in dogs beginning at eight weeks of age.
The company says the new product, which comes in the form of a tasty chewable tablet, acts quickly and provides continuous protection for 35 days without losing efficacy at the end of the month.
Simparica is effective against both Ctenocephalides felis and Ctenocephalides canis flea infestations in dogs.² It starts to kill fleas quickly within three hours³ and continues to kill fleas for at least 35 days², making it suitable as part of a treatment strategy for Flea Allergic Dermatitis.
The product also protects dogs against infestations with the most common ticks found to infest dogs in Europe2,4, including Dermacentor reticulatus, the species associated with the disease babesiosis, which has recently been reported in the UK. It’s also the only treatment for Ixodes hexagonus, one of the most prevalent ticks in the UK. The killing effect against Ixodes ricinus starts within 8 hours after a single oral administration and over 96% are killed within 24 hours.4
Zoetis says Simparica is also effective against Rhipicephalus sanguineus, and Sarcoptes scabiei, and that laboratory evidence shows efficacy for Demodex Canis and Otodectes Cynotis.
Zoetis believes that Simparica’s ability to provide continuous protection up to and beyond the monthly treatment period is very important for pet owners. Sixty three per cent of owners confess to giving flea and tick treatment later than when it was due, with the median being 5 days late.¹ Simparica gives vets and forgetful pet owners the peace of mind of extended duration of activity helping to minimise the potential risk of protection gaps.
Ned Flaxman, companion animal business unit director at Zoetis said: "With Simparica, we bring to the market an advanced parasiticide solution, helping to deliver improved client and pet owner satisfaction. The chewable tablets are easy to administer and readily accepted by dogs. But more importantly, Simparica helps vets and dog owners minimise the potential risk of protection gaps, as it acts very fast to kill fleas and ticks and performs for at least 35 days without losing efficacy — well beyond the monthly treatment period.
"With its rapid onset, robust duration of activity and very good safety profile, Simparica is the only oral isoxazoline indicated for four species of ticks in Europe including Ixodes hexagonus and the two species of fleas, dogs are most frequently infested with. Unlike most treatments, Simparica protects from both types of ectoparasites for the same duration."
For more information please speak to your account manager or contact customer support on 0854 300 8034.
The recognition, management and treatment of pain in calves was identified by the BVA and the BCVA as a priority animal welfare problem following the launch of the BVA’s Animal welfare strategy last year, with the two organisations working closely together to progress an evidence-based best practice position and set of recommendations for the profession.
The new position statement specifically recommends the use of non-steroidal anti-inflammatory drugs (NSAIDs) in addition to local anaesthesia when conducting disbudding and castration in calves, as these are procedures that have been shown to cause acute pain at the time of the procedure and chronic pain afterwards. Analgesics have been shown to reduce the signs of pain in this post-operative period in a wide range of research studies.
The position also recommends the 'Three Rs' approach to castration and disbudding of calves, advocating that, where possible, these procedures are: Replaced by, for example, selecting polled sires to replace disbudding; Reduced by, for example, appropriate use of sexed semen to reduce the number of male calves requiring castration; or Refined, with the use of analgesics.
BVA President Gudrun Ravetz said: "BVA and BCVA’s joint position further reinforces the profession’s focus as animal welfare advocates, and conveys the need for adequate pain management that is reflective of current scientific understanding of pain recognition and treatment in cattle.
"Existing legislation requires a level of anaesthesia and we would encourage veterinary colleagues and stock-keepers to also discuss appropriate analgesic regimes used so that vets prescribe appropriately licensed NSAIDs and other analgesic medicines as required, as part of ensuring a good life for the animals we farm for food."
The recommendations support the University of Nottingham School of Veterinary Medicine and Science’s study, published yesterday in the Veterinary Record, which has found that calf husbandry procedures were significantly less likely to include the use of analgesics in addition to the local anaesthetic (that is routinely used) for other similarly painful procedures. While local anaesthesia can reduce or eliminate much of the acute pain, chronic pain may still remain once the relatively short duration of local anaesthetic action wanes.
John Remnant, a member of BCVA Board and Clinical Assistant Professor in Farm Animal Health and Production at the Nottingham Vet School, said: "It appears that veterinarians’ awareness of pain in cattle and willingness to use analgesics in general has increased over the last decade. However, whilst this should be commended, the apparent lack of use of appropriate analgesia specifically in calves undergoing routine husbandry procedures such as castration and disbudding requires urgent action. I am delighted that the findings of Nottingham University’s study support BVA/BCVA’s statement."
BVA and BCVA’s joint position paper on Analgesia in calves can be found at: https://www.bva.co.uk/uploadedFiles/Content/News,_campaigns_and_policies/Policies/Ethics_and_welfare/Analgesia%20in%20calves%20BVA%20branded.pdf
Photo: A calf in England, New Forest national park. Jim Champion. Wikipedia.
In the study1, which was funded by Universities Federation for Animal Welfare (UFAW), an online questionnaire was completed by 744 snake owners worldwide but predominantly from the UK (68.8%).
The questionnaire investigated housing and husbandry practices and snake health and welfare as measured by clinical signs and behavioural indicators.
Associations between clinical signs, behavioural indicators and housing and husbandry aspects were tested for the three most common snake families: Pythonoids, Boids and Colubrids.
The study found 54.7% of snakes were kept in enclosures shorter in length or height than their body, preventing them from stretching out fully.
10.2% of snakes in the UK were kept in enclosures that do not comply with current recommended guidelines (minimum enclosure length <0.66 of snake length).
Whilst most snake owners (93.1%) reported measuring the temperature in their snakes’ enclosures, 24% of these checked less than the recommended once daily.
When looking at the most commonly owned snake species (royal pythons, corn snakes and common boa constrictors), 47.2% were kept in sub-optimal temperatures for their species.
Furthermore, 48.1% of owners reported not measuring the humidity in their snakes’ enclosure.
Owners reported that many snakes experienced at least one of the listed clinical signs, with the most common issues being skin shedding (28.2%), parasites (11.2%), rostral cuts and scrapes (7.4%) and respiratory problems (5.6%).
Snakes that were kept in enclosures <1 snake length had significantly more clinical signs compared to those snakes kept in enclosures >1 snake length.
Similarly, most snakes were reported to experience at least one of the listed negative behaviours, most commonly interacting with transparent boundaries (52.8%), wincing or withdrawal of head when gently touched (52.4%), putting the head under the substrate (52.1%), unusually high level of activity (51.1%) and attempting to escape (45.9%).
All these negative behaviours have previously been described as associated with captive stress.
Snakes that were reported as having more clinical signs tended to show more reported negative behaviours.
Dr Nicola Rooney, Senior Lecturer in Wildlife and Conservation at Bristol Veterinary School and corresponding author for the paper, said: “Our study has highlighted various concerns for snake welfare.
"The first of these relates to enclosure size, with snakes commonly being kept in vivaria preventing straight-line postures and movement.
"Snakes that were unable to stretch out fully had more clinical signs than those that were able to stretch out fully.
“Whilst we did not find a significant association between temperature or humidity and measures of health and welfare in this study, it is a concern that many snakes were housed in conditions considered sub-optimal for their species.
"We know that appropriate temperature and humidity is vital for maintaining the health of snakes and it would therefore be prudent to investigate these associations further, using methods other than owner reporting.”
Dr Huw Golledge, Animal Welfare Editor-in-Chief, said: “Until now, there has been little empirical data on the housing and husbandry practices of privately kept snakes, and how these impact on their welfare.
"As the first study of this size, this research provides valuable baseline data against which future surveys or welfare interventions can be compared.
“As this survey relies on owner-reported information, it is very likely that many of the frequencies of clinical and behavioural signs are underestimated.
"This demonstrates the need for evidence-based recommendations, and the importance of such recommendations being made accessible to owners to improve snake welfare.”
Reference
Photo: Brown and Black Snake in Close Up Photography © deedee Pexels
The winners and runners up will be honoured at a ceremony taking place on the eve of BSAVA Congress on 3rd April 2019.
Matt Baker, presenter of The One Show and Countryfile, will be hosting the Ceva Animal Welfare Awards alongside the head judge, Chris Laurence MBE FRCVS, who puts his name to the Vet of the Year Award.
The award categories include:
Chris Laurence Vet of the Year – sponsored by Vet Record
Vet Nurse of the Year – sponsored by Agria Pet Insurance
Charity Team of the Year – sponsored by PDSA
Charitable Contribution of the Year – sponsored by Blue Cross
International Cat Care Welfare of the Year – sponsored by International Cat Care
Farmer of the Year – sponsored by R.A.B.I.
Farm Educator of the Year – sponsored by NADIS
Outstanding Contribution to Animal Welfare – sponsored by Your Dog and Your Cat magazines
To nominate someone for an award, visit www.cevawelfareawards.com. They can come from all walks of life and will be assessed on the evidence provided in the original nomination.
Entries must be in by Friday 25 January 2019.
PhotonUVC Vet is a non-contact treatment which emits low dose ultraviolet C light at a targeted area.
Photon Therapeutics says the device kills bacteria, viruses, fungi and other infecting organisms while being safe to host tissues.
Other claimed benefits of the device are that it avoids client compliance issues associated with eye-drops, it eliminates the need for antibiotic eye drops, and it is very simple to learn how to use.
The device costs £4,995.
To explain more about The PhotonUVC Vet, Dr. Simon Dean. MBChB, MSc, FRANZCO, FBCLA Chief Scientific Officer at Photon Therapeutics, and Dr. Mark Leddy BVSc, MBA, CEO, will be delivering a CPD presentation at the Exhibitor Showcase Theatre 3: "5 Amazing Seconds – A New Transformative Treatment for Corneal Infections", on Thursday 14th November at 3pm.
There is also a launch event reception at the stand from 16.15 to 18.15 on Thursday 14 November.
https://photon-therapeutics.com/
The publishers say that many people who prescribe veterinary medicines or who handle them (or bodily fluids that may contain them or their active metabolites) are not aware of the potential harmful effects they can have on human reproduction.
'Handling Veterinary Medicines and Pregnancy' gives up-to-date, evidence-based guidance on which drugs and methods of handling are hazardous; information on the relevant regulations relating to the safe handling of such medicines; and practical guidance on avoiding harm in veterinary practice.
Veterinary Prescriber says that once you have completed the module, you will:
understand the principles of reproductive toxicity
understand how data on the harmful effects of medicines are generated
be aware of the evidence on reproductive harm in veterinary practice
understand what practical measures to take to avoid harm
know where to find helpful information on medicines and pregnancy
For more information, visit: https://www.veterinaryprescriber.org/subscribers/
Dr Neil Bryant from the AHT, who is leading the research, said: "EHV is a major welfare concern for horses and foals and causes emotional, as well as financial strains, on horse owners and breeders around the world. It can strike any horse at any time so a vaccine will be of global welfare benefit to all horses, including the thoroughbred and sports horse breeding industries, and would help control this serious and sometimes fatal disease."
As a viral infection, EHV can cause respiratory disease, abortion or fatal illness in new born foals and neurological disease in adult horses, with signs ranging from slight wobbliness through to complete paralysis. The disease can strike any horse at any time because the virus, like other herpesviruses (such as the cold sore virus in humans), becomes dormant within most horses early in their life. It then re-emerges when the animal is later stressed such as when transported or mixed with new horses. A seemingly healthy pregnant mare may suddenly, and without warning, abort her unborn foal or may show signs of respiratory disease including mild fever, coughing and discharge from the nose. A horse which appears fit and well may suddenly show abnormalities when walking and within hours may be unable to stand.
Despite the potential severity and impact of outbreaks, there is still no vaccine that is licensed to protect against the neurological form of the disease and abortions still occur in highly vaccinated horse populations. The AHT says protection afforded by existing vaccines currently in use is sub-optimal, something that was highlighted by the 2016 abortion storm in Hertfordshire in fully vaccinated animals.
Neil added: "We have become aware of a pressing need for progress towards a new and improved EHV-1 vaccine. Just last month, the AHT was again called upon to work with the racing industry and affected parties in dealing with confirmed cases of EHV-1 abortion in premises in Yorkshire and Suffolk."
To that end, the charity has now established the Equine Industries EHV Vaccine Steering Group. Chaired by Professor Joe Brownlie of the RVC, the steering group includes world-renowned experts on both human and equine herpes viruses from a number of research establishments, who have concluded that the most appropriate way forward is for the AHT to design a modified live virus (MLV) vaccine.
After securing funding from a large number of organisations, including the Alborada Trust, EBM Charitable Trust, Horserace Betting Levy Board and the Racing Foundation, Paul Mellon Estate, Thompson Family Charitable Trust, Coolmore Ireland, Newsells Park Stud, Thoroughbred Breeders’ Association and Juddmonte Farms, the AHT has begun its five-year research programme.
Neil added: "We’re at the beginning of a very exciting and potentially ground-breaking vaccine development. Through our research, we will construct different viruses with attenuating mutations and assess their suitability as MLVs. We hope our findings will enable further development by vaccine manufacturers in creating an effective vaccine to protect against the serious clinical signs induced by EHV-1."
The trial, which was conducted by a UK-French team of researchers from PBD Biotech and Biosellal, is being presented at the European Association of Veterinary Laboratory Diagnosticians (EAVLD) Congress in Brussels today.
Current tests only allow the reliable detection of Mycobacterium avium subspecies paratuberculosis (MAP) from 18-24 month calves and are unable to distinguish between active and passive infection.
For the 16-month trial, calves from three different herds and born from MAP-positive and MAP-negative cows were tested monthly using PBD Biotech’s Actiphage Rapid kit and Biosellal’s Bio-T kit MAP PCR on blood samples, and the same PCR on faeces.
Researchers say the trial proves that early detection of live MAP infection is possible, and paves the way for improved Johne’s disease monitoring and control measures on farms.
Co-Author Dr Ben Swift, Research Fellow in Antimicrobial Resistance at the Royal Veterinary College and R&D Director at PBD Biotech, said: "Young animals are highly susceptible to infection and being able to identify Johne’s disease at this early stage is key to controlling disease spread.
The trial showed that the sensitivity and specificity of Actiphage enables detection of lower levels of MAP than the current culture methods, and provides results in 6 hours rather than weeks."
The Actiphage Rapid technology used in the trial identified live MAP infection at least 4 weeks’ earlier than the faecal PCR in 75% of cases: in one case, the new diagnostic detected MAP in the blood of a one-day old calf born from a MAP-positive cow.
Claire Pelletier, Directrice Générale of BioDev, consultant to Biosellal, will be presenting findings from the trial, which also showed the transient nature of the infection. She said: "The study showed that two calves, identified as MAP-positive by Actiphage-PCR on blood during the first monthly sampling didn’t shed MAP into their faeces until 10 and 11 months. This emphasises that early detection provides a short window of time that allow for control of the disease."
Other international trials using Actiphage are underway to investigate the presence of MAP in milk.
Animalcare has announced the launch of Clavubactin (amoxicillin/clavulanate) for dogs and cats, presented as 4-way split tablets in three strengths to ensure optimum dosing. The three strengths (Clavubactin 50, 250 and 500) contain 50/12.5, 250/62.5 and 500/125mg of amoxicillin and clavulanic acid respectively. Clavubactin 50mg is licensed for cats and dogs. The 250 and 500mg formulation is licensed for dogs only.
According to the company, the increased combined level of active ingredients, compared to some other clavulanate-amoxicillin products on the market, achieves recommended target weight dosing (doses always kept at 12.5mg/kg), even with animals of greater weight, minimising the risk of underdosing.
The 4-way split tablets are designed to facilitate easy and accurate dosing of all sizes of dogs and cats, from 1kg bodyweight (¼ tablet Clavubactin 50) to 50kg (1 tablet Clavubactin 500) and above.
The tablets come in aluminium blister strips of ten tablets in five packaging presentations (Clavubactin 50 and 250 are available in 100 and 250 tablet packs and Clavubactin 500 in 100 tablets).
Animalcare Product Manager Tony Liepman said "Clavubactin allows for optimum target weight dosing and together with the accuracy enabled by SmartTabs easy 4-way split, this gives peace of mind to both vet and client."
The product is supported by dosage charts and dispensing envelopes (the latter is available on request).
For further information contact Animalcare on 01904 487687, speak to your regional Animalcare representative or visit www.animalcare.co.uk/contact-us.
Simon Wootton, Northern European Region CAG Marketing Manager at Idexx said: "It is widely accepted that 1 in 3 cats and 1 in 10 dogs will develop CKD. The adoption by IRIS of the Idexx SDMA™ renal function test is testament to its benefits, and should give vets much more time to intervene and prescribe an appropriate course of action to help improve longevity and quality of life in CKD patients."
Idexx has produced two new wall-charts for practices, intended to assist with the diagnosis, staging and treatment of CKD in dogs and cats. They are being distributed to all practices in the UK, and can also be downloaded from the Idexx website – www.idexx.eu or ordered from Idexx by ringing 00800 1234 33 99.
Under the scheme, 60 students will be given two weeks of supported clinical placements in more than 50 Vets4Pets practices across the UK, helping to prepare them for work in a clinical environment.
Successful applicants will receive £334 per week during their placements and will also have access to a fast-track application to the Vets4Pets Graduate Programme.
Emily Bridges, Vet & Graduate Programme Lead at Vets4Pets said: “While we know that great EMS placements are a key part of a student’s development, we also know that it has become increasingly difficult for students to fund EMS while they are studying.
"By launching the bursary scheme, we’re hoping to provide students with the support they need to get the most out of their placements, without the financial worry."
Jessica Windham, a veterinary graduate from the RVC, London, took part in the pilot. She said: “For me, the bursary helped to pay for my fuel and food while on placement.
"This meant I could go home and rest after eight hours in the practice, instead of going straight to my part-time bar job and working an extra four-hour shift like many students have to do.
"Ultimately because I was less tired, I performed far better as a student and learned a lot more.”
Applications will open in March 2022 for placements beginning in summer, and students can find out more at: www.vets4pets.com/ems
The plans developed by the Animal and Plant Health Agency (APHA), an agency of the Department for Environment, Food & Rural Affairs (DEFRA), involved the creation of a new role of Certification Support Officers (CSOs), non-veterinarians who would support the work of Official Veterinarians (OVs) in the signing of export health certificates for products of animal origin such as meat, dairy, processed products and animal by-products.
The proposals for the creation of CSOs by APHA has arisen due to concerns about the growth of exports in recent years and the potential for an up to 300% increase in products requiring OV certification if the UK has to certify exports of products of animal origin to the EU once the UK leaves the EU. Under APHA’s plans CSOs will work under the direction of veterinary surgeons and support their certification work (for example, verifying temperature checks), although the final certification will always need to be signed by OVs. The role will not involve certification relating to live animals or germinal products.
At the RCVS Council meeting on Thursday 1 November 2018 Council members agreed to facilitate APHA’s proposals and to make changes to the RCVS requirements so as to allow CSOs to support OVs in their certification work.
Amanda Boag, RCVS President, said: "As we have stated in our recent statement on ‘no-deal’ Brexit, it has been estimated that there would be 325% increase in veterinary certification requirements if the UK leaves the EU without a deal, and with these proposals Defra and APHA are preparing for this by increasing the support available for Official Veterinarians. Furthermore the proposal is in line with the concept of a vet-led team, with veterinary surgeons focusing on tasks only vets can do, whilst delegating some tasks to suitably trained and quality-assured members of our teams.
"We appreciate that there were some concerns over the level of education and training required by CSOs and are glad that the APHA has accommodated those views by increasing the level of education to three A-Levels (or equivalent in Scotland) and clarifying the nature of the training required by CSOs.
"By signalling its support for the proposals, RCVS Council has been assured that the integrity and value of the veterinary signature will be upheld and we are glad that we can play a key role in helping the veterinary profession prepare the UK for leaving the EU."
The RCVS position statement on the potential impact of a ‘no-deal’ Brexit scenario is available at www.rcvs.org.uk/brexit
Sarah qualified from the Royal Veterinary College in 1998, gained an MSc in Clinical Oncology in 2003, the RCVS Certificate in Veterinary Dermatology in 2010 and RCVS Advanced Practitioner status in 2015. She is now the President of the British Veterinary Dermatology Study Group.
Sarah previously ran two dermatology referral services before co-founding Vet-AI, a company working on artificial intelligence and an online consultation service for pet owners, where she is now the Chief Veterinary Officer.
Sarah said: "Many diseases that are primarily non-pruritic often become pruritic when the animal develops secondary bacterial or yeast infection. These cases require a thorough dermatologic history and physical examination and successful treatment very often depends on identification of the underlying cause."
"Providing the right nutrition should also be implemented to ensure optimal levels of nutrients required for skin repair, barrier function and health. I will be including a complete pruritus work up, discussing how diet can be part of the management of this particular condition."
To register for the webinar, visit: https://vetportal.royalcanin.co.uk/cpd/webinar/
John Innes, CVS Referrals Director based at Chester Gates Veterinary Specialists (BVSc PhD CertVR DSAS (orth) FRCVS), said: "The main challenges around managing and treating osteoarthritis for vets is that it is a chronic, insidious problem.
"It’s also often lower down the priority list and owners don’t recognise the signs; they often ascribe it to ageing. Actually, osteoarthritis is such a common problem that it should be way up our priority list because something like 10-15% of adult dogs have OA."
The roundtable discussion also focused on the need for greater understanding of the condition among pet owners.
Duncan Lascelles, Professor of Small Animal Surgery and Pain Management at NC State Veterinary Medicine (BSc, BVSc, PhD, MRCVS, CertVA, DSAS(ST), DECVS, DACVS) said: "The vet profession needs to take a much more active role in the education of owners, and osteoarthritis is a perfect example of this. Many owners consider osteoarthritis to be age related and an inevitable part of the ageing process – unfortunately both of those concepts are erroneous.
"Osteoarthritis can be a young dog disease, it is present in many young dogs because it is caused by developmental diseases, but we only recognise the obvious signs later on when the disability is severe. Also, we should not consider OA-related pain as an inevitable part of the ageing process, it is something that we can prevent by early intervention, early treatment and modification of lifestyle."
Meanwhile, a survey of 236 UK practising vets carried out by Elanco last June, revealed that 76% of veterinary surgeons believe owners fundamentally misunderstand OA and consider it just a symptom of old age, which results in a barrier to effective treatment of the disease.
The survey also found that although the illness is commonplace (49% of veterinary surgeons see OA cases every day), vets are often unable to give their preferred treatment for OA for a range of reasons, from owner misconception of the disease through to perceived side effects and compliance.
The issue of better education of owners was also discussed at the roundtable, in particular the role of CMIs (Clinical Metrology Instruments); owner-facing questionnaires designed to help veterinary surgeons evaluate the extent and seriousness of OA-related pain in dogs.
Duncan said: "The great thing about CMIs is that they have been constructed using language that owners understand, therefore are an easy way to ask owners the right questions in the way that they will understand.
"CMIs allow us to have what can be very difficult conversations with owners. Difficult because we have to think of all the different ways that osteoarthritis might be affecting pets. Because the CMIs include pre-constructed questions, it means that conversations with owners are much easier and, importantly, they’re consistent. Consistency is key to ensure you’re asking the same set of questions each time, every time, so you can follow the evolution of clinical signs over time and assess the beneficial impact of our therapeutics."
John added: "We often quiz the owner informally in a consultation, but CMIs gives us the tools needed to formalise this questioning of clients and allow us to put that in context of our knowledge of other patients."
Both John and Duncan said the need for more patient analysis highlighted the need for better use of existing tools, such as the LOAD (‘Liverpool Osteoarthritis in Dogs’) questionnaire, a 13-item clinical metrology instrument (CMI) designed to help veterinary surgeons determine the severity of OA in all dogs, monitor disease progression and assess the patient’s response to treatment.
For more information contact your Elanco representative or call +44 (0)1256 353131.
Invicta, the new, independent veterinary pharmaceutical company, has launched ChroMyco Duo, the first duo plate dermatophtye fungal test to help veterinary professionals identify the source of skin abnormalities in-house without the delay and cost of sending samples to a laboratory.
According to the Sussex-based company, ChroMyco Duo has been designed to aid practices in the accurate identification of fungal skin infections in dogs, cats, horses and all small animal species.
ChroMyco Duo is a dual plate test with dermatophyte test media (DTM) on one side and an Enhanced Sporulation Agar (ESA) on the other. Invicta says it's this dual test capability which greatly reduces the risk of false positive results. The test is performed by veterinary staff taking a pluck of fur or skin scrape from the lesion and innoculating both sides. After three to six days, if dermatophytes are present, the DTM will turn red and the ESA will turn blue-green.
Once a colour change is identified, a sample of the culture can be taken from the ESA, a media prolific in growing dermatophytes. Veterinary staff are then able to examine the fungus microscopically and identify the species of dermatophyte before advising on treatment.
Invicta has prepared a free fungal identification chart to assist practices with the identification of cultures and is providing free updates to subscribers, as images of new fungi are submitted by practices using the kit.
The ChroMyco Duo test is supplied in boxes of five units, each individually wrapped to allow a one year shelf life. It costs £5 per unit, which Invicta says makes it very cost-effective when compared to laboratory charges. It is incubated at room temperature so no specialist equipment is required.
Rob Watkins, Managing Director of Invicta, said: "The incidence of fungal infections in practice is significant and growing. Antifungal treatments already account for more than £1m sales in the UK veterinary sector. The problem is that dermatophyte presence is often misdiagnosed.
"Until recently vets have had to rely on either single test kit, or for a full diagnosis, by sending a sample to laboratory where tests cost up to £20 and can take 14 days to complete.
"With the launch of ChroMyco Duo, we're giving practices the capability to test reliably, simply and cost-effectively for the first time."
For further information on ChroMyco Duo or Invicta, please contact the company on 01403 791313 or email them at mail@invictavet.com.
238 veterinary surgeons responded to the survey which found that 52.3% of practices reported that they do not have all the veterinary surgeons they need, with the average shortfall being 21.6% or approximately 1/5th of the workforce.
28% reported that this lack of vets meant that they are unable to cover their OOH without unacceptable levels of overtime.
88% of practices had tried to recruit in the past 12 months, 31% of which had failed to find a candidate at the time of the survey.
SPVS carried out a similar survey in 2015 and a comparison between the two showed a worsening situation with only 22% of practices finding a new recruit within three months compared to over 30% two years ago. 90% of respondents also felt the recruitment situation had worsened since four years ago.
An unwillingness to do OOH and dissatisfaction with working hours was cited as the most common reason for candidates not accepting a position, mirroring the results of a survey carried out by VetSurgeon Jobs in 2016. This, combined with most respondents saying that personally they planned to reduce their working hours suggests that the crisis can only deepen and that to succeed in recruitment, employers will have to consider more flexible working.
Brian Faulkner, SPVS President said: "This survey provides valuable evidence to support the profession as they work with government and the colleges to try and counter this crisis in recruitment which threatens to get worse with Brexit. If not tackled it will become increasingly difficult for vets to provide a satisfactory 24 hour health service for the UK’s pets, horses and farm animals."
VetSurgeon.org Editor, Arlo Guthrie said: "This is precisely why recruitment adverts on VetSurgeon.org Jobs run for two months rather than the one month typically offered on other websites. In these difficult times, it is also important to try and use every trick in the book to spread the word about your job, and present it in a way that really stands out. On that score, we're working on some new features designed to help good employers stand out from the crowd. Watch this space."
The full survey is available on the SPVS website at: www.spvs.org.uk
Canaural contains fusidic acid, framycetin and nystatin for their antibacterial and antifungal effects against the most common organisms associated with otitis externa.
Fusidic acid has skin penetrating properties and is active against staphylococci and streptococci1. Framycetin is active against Gram negative species. Dechra says the combination of the two provides an enhanced antibacterial effect on the most common bacterial cause of canine otitis2.
Nystatin is active against malassezia and prednisolone helps to provide anti-inflammatory and anti-pruritic action.
Dechra Brand Manager Carol Morgan said: “The reintroduction of Canaural to the veterinary treatment market means that once again veterinarians have this reliable and effective treatment available to tackle one of the most common canine complaints.
"Canaural is a tried and tested product and a recent study showed that fusidic acid is highly efficacious against both methicillin sensitive and methicillin resistant strains of Staphylococcus pseudintermedius3. Canaural remains as relevant today as it has ever been."
Canaural comes in 15 ml and 25 ml bottle sizes and is now available in veterinary wholesalers.
The Council of the Royal College of Veterinary Surgeons has unanimously approved the introduction of a disciplinary system for registered veterinary nurses from 1 April 2011.
The RCVS established the non-statutory Register for Veterinary Nurses in 2007, and says that registration signals a commitment from veterinary nurses to account for their professional practice.
Registered Veterinary Nurses (RVNs) commit to keep their skills up to date via mandatory continuing professional development and abide by the Guide to Professional Conduct for Veterinary Nurses. The disciplinary mechanism is the final component of this regulatory framework. From 1 April 2011, an RVN can be removed or suspended from the Register if found guilty of serious professional misconduct, fraudulent registration or criminal offences affecting his or her fitness to practise.
The decision has been awaited for some time, as according to the College, there has been some dispute about whether an RVN could be removed from the statutory List of Veterinary Nurses (meaning veterinary surgeons would be barred from delegating to them tasks allowed under Schedule 3 to the Veterinary Surgeons Act, such as medical treatment or minor surgery), as well as the non-statutory Register.
Following legal advice that it would not be appropriate to remove someone from a statutory list via a non-statutory regulatory system, RCVS Council and the Veterinary Nurses Council opted for removal from the Register only, with the caveat that any such removed VNs will be clearly identified on the List. In addition, veterinary surgeons will be advised, via the Guide to Professional Conduct, against delegating Schedule 3 tasks to them.
Council also confirmed that it would seek an amendment to Schedule 3 as soon as possible, to enable it to remove the names of nurses found guilty of serious professional misconduct or other charges from the List.
VN Council Chairman Liz Branscombe said: "The Veterinary Nurses Council is committed to moving towards statutory regulation for veterinary nurses. This non-statutory commitment to a disciplinary system is our chance to show government and the public that we are ready and willing to be regulated, which should stand us in good stead for the future."
The RVN disciplinary system will mirror that for veterinary surgeons, with the same complaints-handling, investigation and decision-making processes and sanctions.
Registered Veterinary Nurses will receive more detailed information about the system over the coming months.
According to the BVA’s Voice of the Veterinary Profession survey, 9 out of 10 companion animal veterinary surgeons report that the number of brachycephalic dogs being brought into their practice has greatly increased over the past three years.
98% said they had treated brachycephalic dogs for conformation-related health problems in the past year, and that 56% of the brachycephalic dogs being brought into practice either had, or would have benefited from having treatment for conformation-related health and welfare problems.
49% of UK vets say that the high profile of brachycephalic breeds in social media and advertising is one of the main reasons that clients choose to get a brachycephalic pet.
The #breedtobreathe campaign includes a number of things designed to tackle the problem. Firstly, practices are urged not to use images of brachycephalic dogs in their own marketing materials and communications. In addition the BVA has prepared a toolbox with a template letter for you to send to companies and brands that use brachycephalic breeds in their advertising, together with a range of images and a video you can share on social media, such as Facebook.
BVA President John Fishwick said: "Several well-known brands that use images of flat-faced dogs, such as Costa Coffee, Heinz and Comic Relief, have responded positively to letters from BVA and individual members of the profession recently, and pledged to avoid using them in future campaigns. These seemingly small victories offer hope for greater and long-lasting change.
"While the veterinary profession is relatively small, its reach is significant and its role is critical to the health and welfare of not only animals, but the rest of society too. That is why we believe that it is important for the veterinary team to utilise its spheres of influence both online and offline, which includes avoiding mixed messages between what clients and the wider public are being told by vets and VNs in practice and what they were seeing in practice communications.
"We’re urging vets to continue speaking out on behalf of the animals that we swear an oath to protect, since we know that hearing first-hand from individual members of the vet-led team has a real impact on the brands in question. BVA will continue to support members in challenging irresponsible promotions using these breeds."
The BVA has drawn up a position statement which lists ten actions that veterinary practices can undertake to improve brachycephalic breeds’ health and welfare and promote responsible ownership:
For more information, visit: www.bva.co.uk/brachys.
Photo: ponpimonsa_bibi/Shutterstock
The guide explains:
https://www.rcvs.org.uk/news-and-views/features/standards-and-advice-update-advice-published-on-amended
https://www.gov.uk/government/collections/veterinary-medicines-guidance-notes-vmgns
A former pet industry nutritionist has created a stir in the national newspapers with the launch of whichdogfood.co.uk, a website which dismisses veterinary diets as no different to the "awful" standard pet foods sold in pet stores and supermarkets.
According to reports in the Daily Mail, Daily Telegraph and Daily Express, David Jackson says the objective of his website is to change the way people buy pet food because "pet food manufacturers have been able to get away with producing frankly awful foods for our pets."
Explaining why veterinary surgeon sell prescription diets, Mr Jackson trots out some well known arguments which will be familiar to anyone who has followed the propaganda put out by the raw meaty bones (RMB) lobby: that veterinary surgeons are not taught enough about nutrition; that those training modules that exist are largely sponsored by manufacturers, and that veterinary practices benefit from 'massive cash incentives' from the manufacturers and distributors of veterinary diets.
Mr Jackson does say that there are exceptions to the rule, notably those veterinary diets developed to help pets with intolerance, allergies or uroliths.
The RCVS announced in a tweet yesterday afternoon that it will be retaining postnominals on the Register.
#RCVScouncil agrees to retain postnominals on Register. Proposals to improve clarity to come back to future meeting. — RCVS (@RCVS_UK) June 5, 2014
#RCVScouncil agrees to retain postnominals on Register. Proposals to improve clarity to come back to future meeting.
VetSurgeon understands that the proposals to improve clarity may yet involve some rationalisation of the postnominals that will be displayed, but that RCVS Certs and Diplomas will remain.
The decision represents something of a victory for Victoria Lilley’s campaign and yet another indication that under the stewardship of Nick Stace, the RCVS really is evolving to become a more open, responsive organisation.